10q10k10q10k.net
HARVARD BIOSCIENCE INC

HARVARD BIOSCIENCE INCHBIOEarnings & Financial Report

Nasdaq · life sciences

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

NextMar 14, 2026

HBIO Q3 2025 Key Financial Metrics

Revenue

$20.6M

Gross Profit

$12.0M

Operating Profit

$197.0K

Net Profit

$-1.2M

Gross Margin

58.4%

Operating Margin

1.0%

Net Margin

-6.0%

YoY Growth

-6.3%

EPS

$-0.03

Financial Flow

HARVARD BIOSCIENCE INC Q3 2025 Financial Summary

HARVARD BIOSCIENCE INC reported revenue of $20.6M for Q3 2025, with a net profit of $-1.2M (-6.0% margin). Cost of goods sold was $8.6M, operating expenses totaled $11.8M.

Key Financial Metrics

Total Revenue$20.6M
Net Profit$-1.2M
Gross Margin58.4%
Operating Margin1.0%
Report PeriodQ3 2025

HARVARD BIOSCIENCE INC Annual Revenue by Year

HARVARD BIOSCIENCE INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $94.1M).

YearAnnual Revenue
2024$94.1M
2023$112.3M
2022$113.3M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$28.2M$24.5M$23.1M$22.0M$24.6M$21.8M$20.4M$20.6M
YoY Growth-1.0%-18.2%-19.7%-13.4%-12.8%-11.2%-11.5%-6.3%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$137.4M$133.2M$128.9M$131.2M$126.6M$79.8M$80.1M$78.0M
Liabilities$64.3M$64.3M$61.7M$65.9M$63.3M$65.0M$64.4M$63.9M
Equity$73.1M$68.8M$67.2M$65.3M$63.3M$14.8M$15.7M$14.1M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$4.3M$1.4M$-846000$-842000$1.7M$3.0M$2.8M$1.1M

More Companies

ESCO TECHNOLOGIES INC

ESE

ESCO TECHNOLOGIES INC

Revenue

$289.7M

Net Profit

$28.7M

Legend Biotech Corp

LEGN

Legend Biotech Corp

Revenue

$272.3M

Net Profit

$-39.7M